The Economist Novo Nordisk’s biggest battle may be internal, as it seeks to transform itself from a cautious drugmaker into a nimble consumer brand
Novo Nordisk’s biggest battle may be internal, as it seeks to transform itself from a cautious drugmaker into a nimble consumer brand